key: cord-0914460-sbsyzbse authors: Torrinhas, Raquel S.; Calder, Philip C.; Waitzberg, Dan L. title: Letter to the Editor in relation to Bistrian BR. Parenteral fish oil emulsions in critically ill COVID‐19 emulsions [published online ahead of print, 2020 May 8]. JPEN J Parenter Enteral Nutr. 2020;10.1002/jpen.1871 date: 2020-05-28 journal: JPEN J Parenter Enteral Nutr DOI: 10.1002/jpen.1933 sha: 2c73b94e0d91c3706fa3ea2f413f15f43e90bfbd doc_id: 914460 cord_uid: sbsyzbse In this letter we discuss the proposition of Bristian BR (2020) to use the intravenous administration of fish oil emulsions in critically ill COVID‐19. We consider that immune modulatory properties of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, rapidly provided in high amounts by fish oil emulsion, may be important to change the course of COVID‐19's death pathway. Prescriptions should be based on body weight (e.g. 0.2 g pure FOLE/kg body weight/day) and also should consider combining the parenteral administration of fish oil emulsion to low oral aspirin intake, in order to trigger resolvin synthesis from EPA and DHA. This article is protected by copyright. All rights reserved FOLE/kg body weight/day) and also should consider combining the parenteral administration of fish oil emulsion to low oral aspirin intake, in order to trigger resolvin synthesis from EPA and DHA. Dear Editor, We have read with great interest the letter "Parenteral fish oil emulsions in critically ill COVID-19". 1 As researchers in the field, we recognize the potential benefit of intravenous fish oil lipid emulsion (FOLE) for hospitalized patients affected by Coronavirus Disease 2019 . 2 This approach will allow rapid delivery of high amounts of bioactive forms of omega-3 fatty acids, with helpful immune-modulatory properties, to become available immediately to cells and tissues. 3 We propose that not only obese patients, as suggested by Bistrian 1 , but also several other types of infected patients may benefit from FOLE. Most high-risk populations severely compromised by COVID-19 (elderly, obese, diabetic, hypertensive, oncologic) have a disturbed inflammatory component (e.g. chronic low grade inflammation). [4] [5] [6] [7] We suspect this pre-existing condition may be important in triggering the detrimental hyperinflammation associated to severe COVID-19 phenotypes, which may be attenuated by the omega-3 fatty acids in FOLE. This article is protected by copyright. All rights reserved. Eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, provided by FOLE, have the ability to decrease the synthesis of inflammatory cytokines by modulating gene transcription factors. 3, 8 These include the activation of peroxisome proliferator activated receptor (PPAR), suggested as a therapeutic target to attenuate the cytokine storm in COVID-19. 8-10 Furthermore, these highly unsaturated fatty acids have shown to destabilize rigid membrane lipid rafts. 11 SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) to enter human cells, a cell receptor located at membrane lipid rafts. 12 Importantly, the cytokine storm observed in severe COVID-19 may be a consequence of an impaired inflammatory resolution. The observation that neutrophil extracellular traps (NETs) seem a marker of the disease severity supports this impression. 13 EPA and DHA are essential precursors of resolvins, protectins and maresins, which highly orchestrate the resolution of inflammation. 14 All together, the immune modulatory properties of EPA and DHA may be important to change the course of COVID-19's death pathway. Therefore, as suggested by Bistrian 1 , the use of FOLE as an adjuvant immune-pharmaco-nutrient in COVID-19 seems clinically relevant. 2 . We believe FOLE should be provided on a per body weight basis (e.g. 0.2 g pure FOLE/kg body weight/day) in order to avoid that underweight individuals receive very high amounts of EPA and DHA and that obese individuals receive too low amounts of EPA and DHA. This approach was safe in patients with sepsis and in general critically ill elderly populations. 15, 16 Whether disturbances in systemic metabolism triggered by hyperinflammation may increase the use of EPA and DHA to other purposes than immunomodulation (e.g. energy generation) is unknown. In this sense, it also should be considered to associate low oral aspirin intake in patients with COVID-19 receiving intravenous FOLE. Aspirin can trigger This article is protected by copyright. All rights reserved. resolvin synthesis from EPA and DHA, so its exogenous supply may aid COVID-19 patients to resolve inflammation. 17 Furthermore, similarly to EPA and DHA, aspirin may have a desirable anticoagulant effect for COVID-19 patients. In a Dutch ICU enrolling 184 patients with COVID-19, 38% abnormal blood clotting and 33% formed clots were reported, probably due hyperinflammation. 18, 19 In a model of arteriosclerosis, less aortic plaque lesions and proinflammatory lipid mediators were observed when combining oral fish oil with aspirin than just oral fish oil. 20 In patients with cardio or cerebrovascular ischaemic diseases, this practice was safe and did not affect the risk of upper gastrointestinal complications (e.g. bleeding). 21 Parenteral fish oil emulsions in critically ill COVID-19 emulsions Parenteral fish oil, an adjuvant pharmacotherapy for COVID-19? Fish oil lipid emulsions and immune response: what clinicians need to know Aging, imbalanced inflammation and viral infection Age-related inflammatory cytokines and disease The origins of age-related proinflammatory state Resolution of inflammation in obesity-induced liver disease n-3 fatty acids and gene expression N-3 long chain polyunsaturated fatty acids increase the expression of PPARγ-target genes and resistance of isolated heart and cultured cardiomyocytes to ischemic injury This article is protected by copyright. All rights reserved Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease Modulation of lipid rafts by Omega-3 fatty acids in inflammation and cancer: implications for use of lipids during nutrition support Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2 Neutrophil extracellular traps in COVID-19 Pro-resolving lipid mediators are leads for resolution physiology A randomized controlled trial investigating the effects of parenteral fish oil on survival outcomes in critically ill patients with sepsis: a pilot study Supplemental intravenous n-3 fatty acids and n-3 fatty acid status and outcome in critically ill elderly patients in the ICU receiving enteral nutrition This article is protected by copyright. All rights reserved Inflammation and thrombosis -brothers in arms Addition of aspirin to a fish oil-rich diet decreases inflammation and atherosclerosis in ApoE-null mice Concurrent Use of Low-Dose Aspirin and Omega-3 Fatty Acids and Risk of Upper Gastrointestinal Complications: A Cohort Study with Nested Case-Control Analysis